Treatment Information

Back

Colon Cancer treatment details. Chemotherapy, Biologic therapy.

Vall d'Hebron University Hospital, Barcelona, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:4City/State/Province:Barcelona
Treatments:Chemotherapy, Biologic therapyHospital:Vall d'Hebron University Hospital
Drugs:Journal:Link
Date:Nov 2007

Description:

Patients: This phase II study involved 62 patients with metastatic colorectal cancer. The median age was 65 years, ranging from 43 to 78. Thirty of these patients were men, and 13 were women.

Treatment: Patients were treated with the chemotherapy drugs oxaliplatin, fluorouracil, and leucovorin (FOLFOX) and the biological therapy cetuximab.

Toxicity: Grade 3/4 toxicities were reported in almost all (91%) of patients. The most common grade 3/4 toxicities were diarrhea, neutropenia, and paresthesia (abnormal feeling in the skin such as tingling, numbness, prickling).

Results: The median overall survival was 30 months. The median progression-free survival was 12.3 months.

Support: This study was supported by Merck and Sanofi Aventis. Oxaliplatin is marketed by Sanofi-Aventis as ELOXATIN“ (oxaliplatin injection). Cetuximab is marketed by Merck as Erbitux‘.

Correspondence: Dr. Josep Tabernero





Back